|Articles|March 1, 2019
- Pharmaceutical Executive-03-01-2019
- Volume 39
- Issue 3
Pharmaceutical Executive, March 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Patient Advocacy: The Corporate Mandateover 6 years ago
Patient Support Programs: Cost, Benefit, and Resourcingover 6 years ago
Patients is a Virtueover 6 years ago
What Does Patient Centricity Look Like?over 6 years ago
John Crowley: Living the Missionover 6 years ago
Research Bonds Strengthenalmost 7 years ago
Parallel Trade a Victim of Brexit Collateral Damagealmost 7 years ago
Multiple Pharma Issues Top Congressional Agendaalmost 7 years ago
Pharm Exec Joins MJH Portfolioalmost 7 years ago
Cystic Fibrosis: The Importance of Patient AdvocacyNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
